Teva’s Final Copaxone Firewall Is Complexity Of ANDA Review After Court Tosses Patent
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal Circuit finds claims covering Copaxone’s latest expiring patent are invalid; Mylan says it plans to launch its generic of the MS drug in May 2014.